40% recovery: 4DMedical share price (ASX:4DX) turns sharply and delivers the goods

4DMedical caught bids this week and finished on top.

| More on:
rising medical asx share price represented by excited doctors dancing in ward

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Investors are bidding up the 4DMedical share price hard this week after a key announcement
  • The launch of the company's XV Scanner is a key driver to the commercialisation of its XV Technology strategy, it says
  • In the last 12 months, the 4DMedical share price has sunk by 44%

The 4DMedical Ltd (ASX: 4DX) share price climbed higher on Friday afternoon to close up 1.18% at 85.5 cents.

Investors appear to be rallying behind Thursday's announcement, which revealed the company is launching the world's first dedicated lung scanner.

The 4DMedical share price soared almost 20% yesterday. It's likely that momentum spilled over into today's session as trading volume surged well past its four-week average at 764,665 shares.

With big gains also on Tuesday and Wednesday, it means 4DMedical shares have surged 41% since last Friday's close. This week's gain is a welcome reprieve for 4D shareholders, who've seen their holdings evaporate over the past 12 months.

TradingView Chart

What's been happening at 4DMedical?

The company advised that it has installed the 'XV Scanner' at the Prince of Wales Hospital in Sydney after it was unveiled to the Federal health minister on Thursday.

4D says the scanner will provide unparalleled access to visually map the lung and provides "highly visual insight into lung function".

A successful launch will hopefully see the market adopt its XV Technology, something the company says is integral to successful commercialisation.

But the benefits extend primarily to the doctor-patient realm, and the scanner itself is considered somewhat a "breakthrough in innovation", according to Lung Foundation Australia CEO, Mark Brooke.

It's reported that seven million Australian currently are living with or are impacted by lung disease in some way, therefore any breakthrough would be a welcome sigh of relief to many.

Evans and Partners have 4DMedical rated as a speculative buy and value the company at $1.50 per share, suggesting an upside potential of 75% at the time of writing.

Meanwhile, Bell Potter has the company rated as a speculative hold but sets a price target of $2.07 per share — a mammoth 142% upside potential.

According to Bloomberg data, the consensus valuation is $1.78 per share, still a considerable amount of upside potential if the bull case plays out to that level.

4DMedical share price snapshot

In the last 12 months, the 4DMedical share price has sunk and is now 44% in the red. It is also down 36% this year to date.

Despite the 40% gain this week, shares have still fallen into the red by 5% over the past month.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »